As we progress further into the busy calving season, the risk of milk fever (hypocalcemia) and other metabolic issues, increases.

BridgeBio's launch of Attruby in the U.S. is off to a strong start. Read how this successful effort puts the biotech in a ...

The Food and Drug Administration (FDA) oversees manufacturers of infant formulas and helps ensure that these products are ...

Most adults in the United States with physical chronic health conditions manage them at work but have not told their employer about them, results from a national survey showed.

As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval- ...

BridgeBio’s ATTR cardiomyopathy drug, Attruby, achieved promising sales numbers in the weeks after its FDA approval.

After hours: February 21 at 7:52:05 PM EST Loading Chart for BBIO ...

BridgeBio possesses a medium revenue cyclicality rating, and its operating leverage has a low rating. We assess the company's balance sheet as weak due to management's dependence on debt issuance to ...

Discontinue if new or worsening symptoms occur. Hypocalcemia can worsen and must be corrected prior to use. Severe bone, joint, muscle pain may occur. Discontinue use if severe symptoms develop.

As of February 17, 2025, 1,028 unique patient prescriptions for Attruby have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR ...